We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Double Targeting Approach Increases Potential for Cancer Treatment with Oncolytic Viruses

By LabMedica International staff writers
Posted on 02 Mar 2015
Print article
Image: Typical antibodies (left) unfold in the harsh environment of the cell. Camelid antibodies (right) are smaller and more stable (Photo courtesy of the Washington University School of Medicine).
Image: Typical antibodies (left) unfold in the harsh environment of the cell. Camelid antibodies (right) are smaller and more stable (Photo courtesy of the Washington University School of Medicine).
Cancer researchers have used a double targeting approach to direct oncolytic viruses specifically to tumor cells where they reproduce until the cancer cells burst, releasing more viruses to infect and ultimately destroy the tumor.

Investigators at the Washington University School of Medicine (St. Louis, MO, USA) modified an oncolytic adenovirus in two ways. At the transductional level, antibodies derived from camels or alpacas (camelids) against the tumor protein human carcinoembryonic antigen (CEA) were incorporated into the viral capsid. These antibodies enabled the virus to selectively infect cancer cells. At the transcriptional level, the gene for C-X-C chemokine receptor type 4 promoter was inserted into the viral genome. This gene would only be activated after successful infection of a cancer cell. The dual targeting mechanism was designed to insure that only cancer cells would be infected and destroyed.

Typically, antibodies are composed of two immunoglobulin (Ig) heavy chains and two Ig light chains. Camelids are unique among mammals as they have fully functional antibodies with two heavy chains, but lack the light chains usually paired with each heavy chain. This feature of camelid antibodies prompted their use for viral targeting.

The potential of the modified adenovirus was evaluated with cancer cells growing in culture. The data, which was reported in the February 18, 2015, online edition of the journal Molecular Therapy—Oncolytics, demonstrated that the double targeting approach increased specificity of infection and efficacy of replication of the oncolytic adenovirus.

“For decades, investigators have been putting human or mouse antibodies on viruses, and they have not worked — the antibodies would lose their targeting ability,” said senior author Dr. David T. Curiel, professor of radiation oncology at the Washington University School of Medicine. “It was a technical problem. During replication, the virus is made in one part of the cell, and the antibody is made in another. To incorporate the two, the antibody is dragged through the internal fluid of the cell. This is a harsh environment for the antibodies, so they unfold and lose their targeting ability. We found that when we incorporated the camelid antibodies into the virus, they retained their binding specificity. This opens the door to targeting these antibodies to specific tumor markers.”

“We want this new level of targeting specificity because it would allow us to inject the virus into the bloodstream, where it would exclusively infect and replicate in tumor cells, even if they are disseminated throughout the body,” said Dr. Curiel. “These viruses are already engineered to replicate only in tumors. These camelid antibodies would enable them to become even more tumor-specific and open the door for use in metastatic cancer.”

Related Links:

Washington University School of Medicine


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Liquid Based Cytology Production Machine
LBP-4032
New
Histamine ELISA
Histamine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.